BIGBEAR
PHARMACEUTICAL
Ivosidenib can reduce the production of the oncogenic metabolite 2-HG by selectively targeting and inhibiting the activity of the mutant IDH1 enzyme.
AuthenticGuaranteeFast DeliveryPrivacy Common Adverse Reactions of Ivosidenib1. In patients with acute myeloid leukemia (AML), common adverse reactions (including laboratory abnormalities) ···【More】
Update: 10 Jul,2026Source: BigbearViews: 214
Patients should take Ivosidenib as prescribed by their physician, and at approximately the same time each day.Important Safety Information for Ivoside···【More】
Update: 10 Jul,2026Source: BigbearViews: 202
Management of Adverse Effects of Ivosidenib in Medical Personnel1. Overall Adverse EventsMost common adverse reactions reported in patients with acute···【More】
Update: 10 Jul,2026Source: BigbearViews: 253
Ivosidenib side effects: What are the side effects of Ivosidenib? During the use of Ivosidenib, some adverse reactions may occur. Patients should pay ···【More】
Update: 09 Jul,2026Source: BigbearViews: 192
Ivosidenib Dose Adjustment with Strong CYP3A4 Inhibitors1.If coadministration is unavoidable:reduce ivosidenib dose to 250 mg once daily.2.After disco···【More】
Update: 08 Jul,2026Source: BigbearViews: 210
Ivosidenib Use in Special Populations1. Renal ImpairmentMild to moderate renal impairment (eGFR ≥30 mL/min/1.73m², MDRD formula): no dose adjustment n···【More】
Update: 07 Jul,2026Source: BigbearViews: 193
Ivosidenib recommended dosage is typically 500 mg once daily. Dosage may vary by indication; always follow physician instructions.Ivosidenib Conventio···【More】
Update: 07 Jul,2026Source: BigbearViews: 217
May 2, 2019 (Global Newswire) — Cambridge, MAAgios Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved its supplem···【More】
Update: 06 May,2026Source: BigbearViews: 241
August 25, 2021 – BostonServier Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved Ivosidenib for the treatment o···【More】
Update: 06 May,2026Source: BigbearViews: 236
May 25, 2022, BostonServier announced that the U.S. Food and Drug Administration (FDA) has approved ivonidenib in combination with azacitidine for the···【More】
Update: 06 May,2026Source: BigbearViews: 215
October 24, 2023, Boston, USAServier announced that the U.S. Food and Drug Administration (FDA) has approved ivonidenib for the treatment of patients ···【More】
Update: 06 May,2026Source: BigbearViews: 199
Ivosidenib is used to treat acute myeloid leukemia (AML), cholangiocarcinoma, and myelodysplastic syndromes (MDS) in adult patients with isocitrate de···【More】
Update: 06 May,2026Source: BigbearViews: 228
Ivosidenib Indications1. LeukemiaIvosidenib, used in combination with azacitidine or as monotherapy, is indicated for newly diagnosed acute myeloid le···【More】
Update: 09 Mar,2026Source: BigbearViews: 196
In addition to its expected therapeutic effects, some adverse side effects may occur during treatment with ivosidenib. While not all side effects will···【More】
Update: 09 Mar,2026Source: BigbearViews: 198
Copyright2024@ BIGBEAR All right reserved Bigbear | Bigbear Pharmaceutical | Bigbear Laos
